



Prior to substantive examination, please amend the claims as follows:

In the Claims

Please cancel claims 1-32 and 33-50 without prejudice.

51. (new) A purified preparation of an antibody, or an antigen binding domain thereof, which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
52. (new) A polyclonal antibody preparation enriched for antibodies specifically immunoreactive with a mammalian RAPT1 protein.
53. (new) A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
54. (new) A recombinant antibody including an antigen binding domain which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
55. (new) The preparation of claim 51, wherein the antibody is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
56. (new) The preparation of claim 55, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
57. (new) The preparation of claim 52, enriched for antibodies immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
58. (new) The preparation of claim 57 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
59. (new) The preparation of claim 53, wherein the monoclonal antibody is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
60. (new) The preparation of claim 59, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
61. (new) The preparation of claim 54, wherein the antigen binding domain is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.